COLDPREV – A randomized, double-blind, placebo-controlled inoculation study
COLDPREV – A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold.OJRD, 2017, 7, 125–135.
COLDPREV is a double-blind, placebo-controlled study of healthy volunteers who were inoculated (infected) with a cold virus. The results show a reduction of viral load (by over 99%), as well as a reduction in the number of days with common cold symptoms by over half (54%). Both results are statistically significant compared with placebo.
Reduction in viral load in the upper respiratory tract
Total oropharyngeal viral load for day 3-10
The viral load in the ColdZyme group is reduced with more than -99% compared with placebo (p =0,023)
- Nasal obstruction
- Sore/scratchy throat
The severity of each symptom is rated on a 5-grade scale as:
- 0: “absent”
- 1: “mild”
- 2: “moderate”
- 3: “severe”
- 4: “very severe”